adolescents | CARLAT PUBLISHING

Interpreting Assessment Discrepancies from Multiple Sources

October 17, 2022

In this episode, we will discuss why assessment discrepancies arise, how we can manage them, and what these discrepancies tell us about a patient’s symptoms and response to treatment.

EXPERT Q&A

Assessing and Treating Catatonia in Children and Adolescents

October 1, 2022

Lee Wachtel MD

Lee Wachtel, MD, Medical Director, Neurobehavioral Unit, Kennedy Krieger Institute. Psychiatry Professor, Johns Hopkins School of Medicine. Baltimore, MD.

Dr. Wachtel, expert for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Catatonia is marked by a change from the person’s baseline state with distinct motor, vocal, and behavioral symptoms. Clinicians usually think of a catatonic person as being like a statue—immobile, unresponsive, staring, and with waxy flexibility.

Expert Q&A

Advances in College Mental Health

September 2, 2022

Michelle Riba MD, Garrett Rossi, MD., and Chris Aiken, MD

Michelle B. Riba, MD, MS

Professor, Department of Psychiatry; Co-Director, Workplace Mental Health Solutions, Eisenberg Family Depression Center; Director, PsychOncology Program, University of Michigan Rogel Cancer Center. Editor, College Psychiatry: Strategies to Improve Access to Mental Health (co-editor: Meera Menon, MD).

Interview by Garrett Rossi, MD. Inpatient/consult attending psychiatrist, AtlantiCare Regional Medical Center, Pomona, NJ.

Dr. Riba, expert of this educational activity, has disclosed that she receives book royalties from Springer, Wiley, and APA Publishing. Dr. Aiken has reviewed this educational activity and has determined that there is no commercial bias as a result of this financial relationship. Dr. Rossi has no relevant financial relationship(s) with ineligible companies to disclose.

College life is not what it used to be, and Dr. Riba shares ways to improve psychiatric care for students facing COVID lockdowns, financial strain, and the contagion of campus suicide.

Rethinking Topiramate

August 1, 2022

Chris Aiken, MD and Kellie Newsome, PMHNP

Topiramate can cause psychosis, or treat psychosis; worsen cognition, or improve it; cause depression or… You get the point. A look at the paradoxical world of psychopharmacology.

Medication Management of Antipsychotic-Induced Weight Gain in Children and Teens

July 25, 2022

Joshua Feder, MD and Mara Goverman

Second-generation antipsychotics routinely breach the FDA’s level of concern of >7% body weight gain. This article examines the efficacy and safety of using off-label medications, such as metformin, to manage this side effect.

How Effective is Atomoxetine in Children and Adolescents

June 27, 2022

Joshua Feder, MD and Mara Goverman

With the recent approval of another non-stimulant ADHD medication (viloxazine, brand name Qelbree), this is a good time to revisit atomoxetine.

Intravenous Ketamine for Teen Depression

January 31, 2022

Pavan Madan, MD.

Pavan Madan, MD. Dr. Madan has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Ketamine is a hot topic in the treatment of adults with severe depression. But how effective is ketamine in adolescents? This research update looks at some emerging data to help you decide whether off label use of ketamine might be a viable option in teens with severe depression.

Teen Drinking: Risks and Responses

July 14, 2021

Amy Yule, MD

Amy Yule, MD
Director of Adolescent Addiction Psychiatry, Boston Medical Center, Boston, MA. Dr. Yule has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

What is the problem with a little teenaged experimentation with alcohol? Don’t most kids do it? Learn the risks related to this ubiquitous substance and help protect your patients from potentially life altering or life-threatening outcomes now and for their futures.

The Effect of Age and Pubertal Stage on Mental Health in Gender-Incongruent Youths

May 20, 2021

John Raiss, MD.

John Raiss, MD. Dr. Raiss has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

When is the best time to begin gender affirming medical care (GAMC) with respect to addressing the mental health status of children and adolescents with Gender Dysphoric Disorder? Should we begin Hormone Replacement Therapy early or wait until the adolescent is older? This research update will help you grapple with this very public debate.

EXPERT Q&A

Duty to Warn? Debating Antidepressant Suicidality

October 30, 2020

Martha J. Ignaszewski, MD and Glen Spielmans, PhD

Martha J. Ignaszewski, MD
Fellow, University of California, San Francisco

Glen Spielmans, PhD
Professor of Psychology, Metropolitan State University, St. Paul, MN

Dr. Ignaszewski and Dr. Spielmans have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

For 16 years, since the FDA black box warning about suicidality with antidepressants, our community has been quoting data that downplays this concern. We were wrong. We were deceived. Antidepressants can be lifesaving, but there really is a duty to warn. Drs. Martha Ignazewski and Glen Speilmans talk with us about what went on and how to talk about it with our families.